Image may be NSFW.
Clik here to view.
The FDA today approved Sanofi‘s (NYSE:SNY) Admelog insulin lispro injection. The product is indicated to help adults and kids with Type I and Type II diabetes control their blood sugar levels.
Admelog is the first short-acting insulin approved using the FDA’s 505(b)(2) pathway.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Sanofi’s short-acting insulin lispro injection appeared first on MassDevice.
